Cargando…
Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway
Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841021/ https://www.ncbi.nlm.nih.gov/pubmed/28276313 http://dx.doi.org/10.3727/096504017X14886444100783 |
_version_ | 1783643708054306816 |
---|---|
author | Tan, Wenliang Zhu, Sicong Cao, Jun Zhang, Lei Li, Wenda Liu, Kairui Zhong, Jinyi Shang, Changzhen Chen, Yajin |
author_facet | Tan, Wenliang Zhu, Sicong Cao, Jun Zhang, Lei Li, Wenda Liu, Kairui Zhong, Jinyi Shang, Changzhen Chen, Yajin |
author_sort | Tan, Wenliang |
collection | PubMed |
description | Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib is necessary to improve the antitumor efficiency. Here we demonstrated that expression of MMP-2 is positively correlated with the migration ability of HCC cells. Cells with a higher MMP-2 expression (SK-HEP-1 cells) were less sensitive to sorafenib than those with lower MMP-2 expression (HepG2 cells). Cotreatment of cells with SB-3CT and sorafenib more strongly inhibited migration ability than with sorafenib treatment alone in both HCC cells with high and low expression of MMP-2. In vivo cell metastasis experiments confirmed the synergistic effects of sorafenib and SB-3CT in reducing lung metastasis of SK-HEP-1 cells. Mechanistically, we showed that the synergistic antitumor effect may be attributed to inhibition of the PI3K/AKT/mTOR signaling pathway, but not the RAF/MEK/ERK signaling pathway. With these results taken together, the current study demonstrates that inhibiting MMP-2 expression can enhance the antitumor effect of sorafenib in HCC cells with a high MMP-2 expression, which may provide a novel strategy to improve therapeutic efficiency in HCC. |
format | Online Article Text |
id | pubmed-7841021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Cognizant Communication Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-78410212021-02-16 Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway Tan, Wenliang Zhu, Sicong Cao, Jun Zhang, Lei Li, Wenda Liu, Kairui Zhong, Jinyi Shang, Changzhen Chen, Yajin Oncol Res Article Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib is necessary to improve the antitumor efficiency. Here we demonstrated that expression of MMP-2 is positively correlated with the migration ability of HCC cells. Cells with a higher MMP-2 expression (SK-HEP-1 cells) were less sensitive to sorafenib than those with lower MMP-2 expression (HepG2 cells). Cotreatment of cells with SB-3CT and sorafenib more strongly inhibited migration ability than with sorafenib treatment alone in both HCC cells with high and low expression of MMP-2. In vivo cell metastasis experiments confirmed the synergistic effects of sorafenib and SB-3CT in reducing lung metastasis of SK-HEP-1 cells. Mechanistically, we showed that the synergistic antitumor effect may be attributed to inhibition of the PI3K/AKT/mTOR signaling pathway, but not the RAF/MEK/ERK signaling pathway. With these results taken together, the current study demonstrates that inhibiting MMP-2 expression can enhance the antitumor effect of sorafenib in HCC cells with a high MMP-2 expression, which may provide a novel strategy to improve therapeutic efficiency in HCC. Cognizant Communication Corporation 2017-11-02 /pmc/articles/PMC7841021/ /pubmed/28276313 http://dx.doi.org/10.3727/096504017X14886444100783 Text en Copyright © 2017 Cognizant, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License. |
spellingShingle | Article Tan, Wenliang Zhu, Sicong Cao, Jun Zhang, Lei Li, Wenda Liu, Kairui Zhong, Jinyi Shang, Changzhen Chen, Yajin Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway |
title | Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway |
title_full | Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway |
title_fullStr | Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway |
title_full_unstemmed | Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway |
title_short | Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway |
title_sort | inhibition of mmp-2 expression enhances the antitumor effect of sorafenib in hepatocellular carcinoma by suppressing the pi3k/akt/mtor pathway |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841021/ https://www.ncbi.nlm.nih.gov/pubmed/28276313 http://dx.doi.org/10.3727/096504017X14886444100783 |
work_keys_str_mv | AT tanwenliang inhibitionofmmp2expressionenhancestheantitumoreffectofsorafenibinhepatocellularcarcinomabysuppressingthepi3kaktmtorpathway AT zhusicong inhibitionofmmp2expressionenhancestheantitumoreffectofsorafenibinhepatocellularcarcinomabysuppressingthepi3kaktmtorpathway AT caojun inhibitionofmmp2expressionenhancestheantitumoreffectofsorafenibinhepatocellularcarcinomabysuppressingthepi3kaktmtorpathway AT zhanglei inhibitionofmmp2expressionenhancestheantitumoreffectofsorafenibinhepatocellularcarcinomabysuppressingthepi3kaktmtorpathway AT liwenda inhibitionofmmp2expressionenhancestheantitumoreffectofsorafenibinhepatocellularcarcinomabysuppressingthepi3kaktmtorpathway AT liukairui inhibitionofmmp2expressionenhancestheantitumoreffectofsorafenibinhepatocellularcarcinomabysuppressingthepi3kaktmtorpathway AT zhongjinyi inhibitionofmmp2expressionenhancestheantitumoreffectofsorafenibinhepatocellularcarcinomabysuppressingthepi3kaktmtorpathway AT shangchangzhen inhibitionofmmp2expressionenhancestheantitumoreffectofsorafenibinhepatocellularcarcinomabysuppressingthepi3kaktmtorpathway AT chenyajin inhibitionofmmp2expressionenhancestheantitumoreffectofsorafenibinhepatocellularcarcinomabysuppressingthepi3kaktmtorpathway |